170 related articles for article (PubMed ID: 36858519)
1. Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.
Sumii M; Namba M; Tokumo K; Yamauchi M; Okamoto W; Hattori N; Sugiyama K
Intern Med; 2023 Oct; 62(20):3001-3004. PubMed ID: 36858519
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
Boeschen M; Kuhn CK; Wirtz H; Seyfarth HJ; Frille A; Lordick F; Hacker UT; Obeck U; Stiller M; Bläker H; von Laffert M
Lung Cancer; 2023 Oct; 184():107361. PubMed ID: 37699269
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
4. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
[TBL] [Abstract][Full Text] [Related]
6. Probing Mutant KRAS, STK11, KEAP1 in NSCLC.
Cancer Discov; 2022 Oct; 12(10):2226. PubMed ID: 35997519
[TBL] [Abstract][Full Text] [Related]
7. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
8. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
[TBL] [Abstract][Full Text] [Related]
9. Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level.
Bazhenova L
Ann Oncol; 2023 Apr; 34(4):327-332. PubMed ID: 37061249
[No Abstract] [Full Text] [Related]
10. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
[TBL] [Abstract][Full Text] [Related]
11. Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Kus T; Aktas G
J Thorac Oncol; 2022 Jun; 17(6):e63-e64. PubMed ID: 35623683
[No Abstract] [Full Text] [Related]
12. In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
Kus T; Aktas G
J Thorac Oncol; 2023 Aug; 18(8):e83-e84. PubMed ID: 37479333
[No Abstract] [Full Text] [Related]
13. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
[TBL] [Abstract][Full Text] [Related]
14. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
[TBL] [Abstract][Full Text] [Related]
15. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
16. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
Provencio-Pulla M; Pérez-Parente D; Olson S; Hasan H; Balea BC; Rodríguez-Abreu D; Piqueras ML; Pal N; Wilkinson S; Vilas E; Ruiz-Gracia P; Cobo-Dols M
Clin Transl Oncol; 2024 Jun; 26(6):1384-1394. PubMed ID: 38183584
[TBL] [Abstract][Full Text] [Related]
17. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
18. STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.
Dziadziuszko R
J Thorac Oncol; 2022 Mar; 17(3):351-352. PubMed ID: 35216730
[No Abstract] [Full Text] [Related]
19. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Ricciuti B; Son J; Okoro JJ; Mira A; Patrucco E; Eum Y; Wang X; Paranal R; Wang H; Lin M; Haikala HM; Li J; Xu Y; Alessi JV; Chhoeu C; Redig AJ; Köhler J; Dholakia KH; Chen Y; Richard E; Nokin MJ; Santamaria D; Gokhale PC; Awad MM; Jänne PA; Ambrogio C
Clin Cancer Res; 2022 Apr; 28(8):1640-1650. PubMed ID: 35091439
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]